Related Experiment Video

Updated: May 25, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Targeting myocardial substrate metabolism in heart failure: potential for new therapies

Hossein Ardehali1, Hani N Sabbah, Michael A Burke

  • 1Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. h-ardehali@northwestern.edu

European Journal of Heart Failure
|January 19, 2012
PubMed

Insights

Heart failure patients have altered cardiac metabolism, with a shift from fatty acids to glucose and reduced ATP. Targeting these metabolic changes offers a promising therapeutic strategy for heart failure.

Area of Science:

  • Cardiology
  • Biochemistry
  • Molecular Biology

Background:

  • Heart failure incidence and prevalence are rising globally.
  • Patients with heart failure often have viable but dysfunctional heart muscle.
  • Cardiac metabolism in heart failure is understudied despite its potential therapeutic relevance.

Purpose of the Study:

  • To review metabolic alterations in heart failure, focusing on fatty acid and glucose metabolism, and AMP-activated kinase.
  • To highlight the potential of targeting cardiac energetics for heart failure treatment.
  • To advocate for increased research into cardiac metabolic pathways for novel therapeutic development.

Main Methods:

  • Review of existing literature on cardiac metabolism in heart failure.
  • Analysis of metabolic shifts, including substrate utilization (fatty acid vs. glucose) and ATP levels.
  • Examination of the role of AMP-activated kinase in heart failure pathophysiology.

Main Results:

  • Heart failure is associated with altered cardiomyocyte energetics.
  • A shift from fatty acid to glucose as the preferred metabolic substrate occurs in heart failure.
  • Reduced adenosine triphosphate (ATP) levels are observed in failing hearts.

Conclusions:

  • Current heart failure therapies do not target metabolic pathways.
  • Understanding cardiac metabolic regulation is crucial for developing new treatments.
  • Targeting myocardial energetics in viable heart tissue presents a promising therapeutic avenue for heart failure.

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...